Gilead Sciences in Charts: Revenue From Major Products Rises Y/Y in Q3

Seeking Alpha06:58

Gilead Rises as It Raises 2024 Sales, Non-GAAP EPS Outlook

Seeking Alpha06:48

Gilead Sciences Raises FY24 Product Sales Guidance From $27.10B - $27.50B To $27.80B - $28.10B

Benzinga05:39

Gilead Sciences Non-GAAP EPS of $2.02 Beats by $0.47, Revenue of $7.55B Beats by $550M

Seeking Alpha05:05

SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?

Seeking Alpha04:17

Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry

BenzingaNov 6 23:00